Alicia Ciccone, Digital Content Editor

Dr Richard Lipton and Dr Paul Martin debated the pros and cons of trigger avoidance in patients with migraine headache at the 2018 American Headache Society Annual Scientific Meeting in San Francisco, California.

The CaMEO study is a prospective, longitudinal web-based survey designed to characterize the impact of migraine on aspects of quality of life.

The investigators assessed participants for photophobia, unilateral location, phonophobia, exacerbation, nausea, pulsatility, sensory aura, pain level and frequency, visual aura, and allodynia features.

The treatment may be beneficial in patients whose acute migraine does not respond to standard treatment with intravenous metoclopramide.

The first-in-class migraine prevention drug will be available to patients within 1 week of the approval.

Complete results from 2 phase 3 trials examining the effects of 2 humanized monoclonal antibodies in patients with episodic and chronic migraine were published simultaneously.

Adjunctive subcutaneous belimumab plus standard care improves SLE Responder Index response and decreases disease flares

Patients with multiple sclerosis (MS) have lower bone mineral density and greater rates of osteoporosis than healthy controls.

In a phase 3 trial, treatment with erenumab reduced migraine frequency, monthly migraine days, and migraine medication use in patients with episodic migraine.

In patients with sciatica pain, treatment with pregabalin did not significantly reduce pain intensity compared with placebo.